{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:23:37Z","timestamp":1792153417536,"version":"4.4.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Minimal change disease and focal segmental glomerulosclerosis are primary podocytopathies that are clinically presented in adults presenting with severe nephrotic syndrome. The pathogenesis of these diseases is not clear and many questions remain to be answered. A new concept about the role of changes in the antigenic determinant of podocytes and the production of anti-podocyte antibodies that cause podocyte damage is being developed. The aim of the study is to evaluate the levels of anti-CD40 and anti-ubiquitin carboxyl-terminal hydrolase L1 (anti-UCH-L1) antibodies in patients with podocytopathies in comparison with other glomerulopathies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred and six patients with glomerulopathy and 11 healthy subjects took part in the study. A histological study revealed primary FSGS in 35 patients (genetic cases of FSGS and secondary FSGS in the absence of NS were excluded), 15 had MCD, 21 - MN, 13 - MPGN, 22 patients - IgA nephropathy. The effect of steroid therapy was evaluated in patients with podocytopathies (FSGS and MCD). The serum levels of anti-UCH-L1 and anti-CD40 antibodies were measured by ELISA before steroid treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The levels of anti-UCH-L1 antibodies were significantly higher in MCD patients and anti-CD40 antibodies were higher in MCD and FSGS than in the control group and other groups of glomerulopathies. In addition, the level of anti-UCH-L1 antibodies was higher in patients with steroid-sensitive FSGS and MCD, and anti-CD40 antibodies were lower than in patients with steroid-resistant FSGS. An increase in anti-UCH-L1 antibody levels above 6.44\u2009ng\/mL may be a prognostic factor of steroid-sensitivity. The ROC curve (AUC\u2009=\u20090.875 [95% CI 0.718\u20130.999]) for response to therapy showed a sensitivity of 75% and specificity of 87.5%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>An increase in the level of anti-UCH-L1 antibodies is specific for steroid-sensitive FSGS and MCD, while an increase in anti-CD40 antibodies \u2013 for steroid-resistant FSGS, compared with other glomerulopathies. It suggests that these antibodies could be a potential factor for differential diagnosis and treatment prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1189017","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T10:26:58Z","timestamp":1687256818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Preliminary study of anti-CD40 and ubiquitin proteasome antibodies in primary podocytopaties"],"prefix":"10.3389","volume":"10","author":[{"given":"Natalia","family":"Chebotareva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venzsin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoliy","family":"Vinogradov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Alentov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Sergeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Kononikhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","article-title":"Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997","volume":"30","author":"Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1523-1755.2004.00833.x","article-title":"Clinicopathologic correlations of renal pathology in Spain","volume":"66","author":"Rivera","year":"2004","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.mayocp.2017.09.011","article-title":"The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study","volume":"92","author":"Hommos","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.ajkd.2016.03.416","article-title":"Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000-2011 among a racially and ethnically diverse US population","volume":"68","author":"Sim","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.trsl.2015.03.002","article-title":"Janus kinase 2\/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier","volume":"166","author":"Sharma","year":"2015","journal-title":"Transl Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/nejm199604043341402","article-title":"Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis","volume":"334","author":"Savin","year":"1996","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMc1202500","article-title":"Resolution of recurrent focal segmental glomerulosclerosis after retransplantation","volume":"366","author":"Gallon","year":"2012","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00467-009-1214-x","article-title":"T regulatory cell function in idiopathic minimal lesion nephrotic syndrome","volume":"24","author":"Araya","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00467-010-1676-x","article-title":"Minimal change disease: a \"two-hit\" podocyte immune disorder?","volume":"26","author":"Shimada","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","article-title":"The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephritic syndrome","volume":"24","author":"Shao","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrneph.2013.183","article-title":"Targeting co-stimulatory pathways: transplantation and autoimmunity","volume":"10","author":"Ford","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1155\/2015\/714964","article-title":"Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family","volume":"2015","author":"Savin","year":"2015","journal-title":"J Immunol Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2249.2005.02862.x","article-title":"Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome","volume":"141","author":"Musante","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.21037\/atm-21-3988","article-title":"The important roles and molecular mechanisms of annexin A2 autoantibody in children with nephrotic syndrome","volume":"9","author":"Ye","year":"2021","journal-title":"Ann Transl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting Nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"256ra136","DOI":"10.1126\/scitranslmed.3008538","article-title":"A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation","volume":"6","author":"Delville","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaut.2017.12.014","article-title":"Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice","volume":"89","author":"Jamin","year":"2018","journal-title":"J Autoimmun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ndt\/gfw443","article-title":"Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies","volume":"33","author":"Mariani","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"ref22","first-page":"622","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","author":"Andrassy","year":"2013"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"JASN"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/path.2511","article-title":"UCH-L1 expression of podocytes in diseased glomeruli and in vitro","volume":"217","author":"Liu","year":"2009","journal-title":"J Pathol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.uct.2007.06.001","article-title":"Anti-CD40 agonist antibodies: preclinical and clinical experience","volume":"2","author":"Khalil","year":"2007","journal-title":"Update Cancer Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00467-012-2163-3","article-title":"TNF\u03b1 pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and \u03b23 integrin activation","volume":"27","author":"Bitzan","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e40589","DOI":"10.1371\/journal.pone.0040589","article-title":"Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus","volume":"7","author":"Veron","year":"2012","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"F138","DOI":"10.1152\/ajprenal.00122.2008","article-title":"Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (Palb)","volume":"297","author":"Charba","year":"2009","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1189017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T10:27:00Z","timestamp":1687256820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1189017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":30,"alternative-id":["10.3389\/fmed.2023.1189017"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1189017","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"article-number":"1189017"}}